Mice Model Market by Model Types (Inbred, Outbred, Hybrid), Services (Breeding, Rederivation), Technology (Microinjection, CRISPR/Cas9), Therapeutic Area (Oncology, Neurology, Immunology), Application (Research, Drug Discovery) & Region - Global Forecast to 2029
Report Code: BT 2192 Feb, 2024, by marketsandmarkets.com
The global mice model market in terms of revenue was estimated to be worth $1.5 billion in 2024 and is poised to reach $2.2 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The expansion of the market is primarily propelled by their genetical identity with humans, resulting in greater reproducibility of experimental results. The rising pipeline of novel drug therapies is also supporting the growth of this market.
Mice Model Market- Global Forecast to 2029
To know about the assumptions considered for the study, Request for Free Sample Report
Attractive Opportunities in the Mice Model Market
Global Mice model Market Dynamics
DRIVER: Rising demand for personalized medicines in oncology
The increasing incidence and prevalence of chronic diseases like cancer is a pivotal driving factor behind the burgeoning growth of the market. As diseases such as cancer, become more prevalent, personalized medicine approaches facilitated by mice model research are gaining prominence. For instance, the rising number of cancer cases has led to a demand for tailored treatments based on individual genetic profiles, driving the adoption of drug development strategies. According to World Health Organization estimates, worldwide, an estimated 20 million new cancer cases and 10 million cancer-related deaths occurred in 2020. Projections suggest a frightening 60% surge in the cancer burden within the next two decades, imposing greater strain on healthcare systems, individuals, and communities. This market growth is further fueled by the need for more effective and personalized therapeutic interventions in the face of a growing global health burden.
RESTRAINT: Ethical concerns and regulatory interventions
Ethical concerns and regulatory constraints pose significant impediments to the market, necessitating careful consideration by researchers and organizations such as biosafety considerations, GLP compliance standards, and animal welfare compliance. The ethical considerations surrounding animal use in scientific research, particularly with mice models, have intensified, placing greater emphasis on humane treatment. Entities engaged in biomedical research are obligated to strictly adhere to ethical guidelines, prioritizing the humane care and welfare of animals involved in experiments. Despite concerted efforts to prioritize the well-being of mice in research, persistent concerns revolve around potential pain, distress, and suffering. Ethical dilemmas arise from issues such as insufficient housing, painful procedures, and a lack of enrichment activities, prompting critical reflections on the ethical treatment of these animals. These challenges, rooted in ethical considerations, not only impede the growth of the market but also prompt crucial reflections on striking a balance between scientific advancements and the ethical treatment of animals.
OPPORTUNITY: Rising demand for disease specific mice models
The rising demand for disease-specific mouse models presents a substantial growth opportunity within the market. Researchers and pharmaceutical companies increasingly recognize the importance of tailored models that faithfully replicate specific human diseases, enabling more accurate preclinical studies and therapeutic development. For instance, the rising prevalence of cancer-related research has led to a surge in demand for mouse models engineered to mimic distinct types of cancer, facilitating detailed investigations into disease mechanisms and the evaluation of potential treatments. Moreover, the demand for neurodegenerative disease models, such as Alzheimer's and Parkinson's, is on the rise, reflecting a growing emphasis on understanding and addressing complex neurological disorders. For instance, Mice models with induced Alzheimer's or Parkinson's disease are crucial for understanding these complex neurological conditions and testing potential therapies.
CHALLENGE: Genetic & Phenotypic variability
The challenge of genotype and phenotypic variability poses a complex obstacle in the market. Genetic diversity within mouse strains, even those considered to be inbred, can result in variations in both genotype and phenotype. This variability can influence research outcomes, hindering the reproducibility and reliability of experimental results. For instance, in studies related to drug development or disease modeling, subtle genetic differences among individual mice can lead to diverse responses to treatments, making it challenging to draw consistent conclusions. Additionally, factors such as environmental conditions, housing, and diet can further contribute to phenotypic variations among mice within the same strain. This inherent variability complicates the establishment of standardized protocols and can increase the difficulty of comparing results across different studies or research facilities.
Global Mice Model Industry Ecosystem Analysis
The mice model market ecosystem comprises raw material suppliers, product/model & service providers, regulatory authorities, and end users, such as academic & research institutes, contract research organizations, and pharmaceutical & biotechnology companies
CRISPR/Cas9 segment held a dominant share in the technology segment in the mice model industry
Based on the technology, the mice model market has been segmented into CRISPR/CAS9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies. In 2023, CRISPR/Cas9 accounted for the largest share of the market. This is attributed to its capacity to offer in-depth insights into individual genetic variations, enabling personalized medicine by optimizing drug selection based on unique genetic profiles.
The drug discovery & development segment of mice model industry is expected to register fastest growth during the forecast period.
Based on the application, the mice model market has been segmented into drug discovery & development, research application, and personalized medicine. In 2023, drug discovery & development accounted for the largest market share and is expected to achieve the highest CAGR during the projected period. The key drivers of drug discovery & development in the market include their ability of mice model to mimic human physiology and disease pathology. Mice models share genetic, physiological, and behavioral similarities with humans, making them valuable tools for studying disease mechanisms, evaluating drug efficacy, and assessing safety profiles
North America accounted for the largest share in mice model industry in 2023
Geographically, the mice model market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and the Africa. North America held the dominant share followed by Europe. North America has been a leader in supporting research for the development of innovative in new therapy. Thus, the development of novel therapies and R&D efforts taken by countries such as US and Canada, and rising number of preclinical research projects in the region are contributing to the growth of the North America market.
To know about the assumptions considered for the study, download the pdf brochure
Key players in the global mice model market include Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), GemPharmatech (China), Cyagen (US), Shanghai Model Organisms Center, Inc. (China), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan), Ozgene Pty Ltd. (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Harbour BioMed (China), Marshall BioResources (US), genOway (France), Vivo Bio Tech Ltd. (India), ingenious targeting laboratory (US), Janvier Labs (France), Applied StemCell (US), Creative Animodel (US), JOINN Laboratories Co., Ltd. (China), Creative Biolabs (US), Crescendo Biologics (UK), Aragen Life Sciences (India), and PolyGene (Switzerland).
Scope of the Mice Model Industry
|
Report Metric |
Details |
|
Market Revenue in 2024 |
$1.5 billion |
|
Projected Revenue by 2029 |
$2.2 billion |
|
Revenue Rate |
Poised to Grow at a CAGR of 8.1% |
|
Market Driver |
Rising demand for personalized medicines in oncology |
|
Market Opportunity |
Rising demand for disease specific mice models |
This report categorizes the mice model market to forecast revenue and analyze trends in each of the following submarkets:
By Model Type & Service
-
Model Type
- Inbred Mice
- Genetically Engineered Mice
- Hybrid/Congenic Mice
- Outbred Mice
-
Service
- Breeding
- Cryopreservation
- Rederivation
- Quarantine
- Other services
By Technology
- CRISPR/CAS9
- Microinjection
- Embryonic Stem cell Injection
- Nuclear Transfer
- Other Technologies
By Therapeutic Area
- Oncology
- Metabolic Diseases
- Immunology
- Neurology
- Cardiovascular Diseases
- Other Therapeutic Diseases
By Application
- Drug Discovery & Development
- Research Application
- Personalized Medicine
By End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- CROs & CDMOs
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
-
Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
-
Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLATAM)
-
Middle East & Africa
-
Middle East
-
GCC Countries
- Saudi Arabia
- United Ara Emirates
- Rest of GCC Countries
- Rest of Middle East (RoME)
-
GCC Countries
- Africa
-
Middle East
Recent Developments of Mice Model Industry:
- In December 2023, Biocytogen entered into a licensing agreement with Nuerocrine Biosciences. This agreement grants Neurocrine Biosciences the right to license selected antibodies for therapeutic product development, manufacturing, and commercialization for all uses worldwide.
- In July 2022, GemPharmatech has entered into a strategic licensing agreement with Charles River Laboratories to distribute its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America.
- In April 2022, Inotiv acquired Histion, LLC. The acquisition is a strategic development that reflects the company’s capabilities in expanding capabilities for surgical models and pathology services.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global mice model Market?
The global mice model market boasts a total revenue value of $2.2 billion by 2029.
What is the estimated growth rate (CAGR) of the global mice model Market?
The global mice model market has an estimated compound annual growth rate (CAGR) of 8.1% and a revenue size in the region of $1.5 billion in 2024. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 51)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 REGIONS COVERED
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 LIMITATIONS
1.8 SUMMARY OF CHANGES
1.9 RECESSION IMPACT
2 RESEARCH METHODOLOGY (Page No. - 57)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 MICE MODEL MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MICE MODEL INDUSTRY SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
2.2.1 BOTTOM-UP APPROACH
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
FIGURE 5 ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES: REVENUE SHARE ANALYSIS (2023)
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 TOP-DOWN APPROACH
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 GROWTH FORECAST
FIGURE 8 MARKET: CAGR PROJECTIONS
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.6 RESEARCH ASSUMPTIONS
2.7 MARKET FORECAST
TABLE 1 FACTOR ANALYSIS
2.8 RISK ANALYSIS
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 68)
FIGURE 10 MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2024 VS. 2029 (USD MILLION)
FIGURE 11 MICE MODEL INDUSTRY, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 12 MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
FIGURE 13 MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF MARKET
4 PREMIUM INSIGHTS (Page No. - 72)
4.1 MICE MODEL MARKET OVERVIEW
FIGURE 15 RISING INVESTMENTS AND ADVANCEMENTS IN MOUSE MODEL TECHNOLOGY TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: MARKET, BY MODEL TYPE & SERVICE (2023)
FIGURE 16 MODEL TYPE SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
4.3 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
4.4 MARKET SHARE, BY END USER
FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 75)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 MICE MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 2 MICE MODEL INDUSTRY: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 High adoption of mice models in preclinical studies
5.2.1.2 Increasing demand for mouse clinical trials (MCTs)
5.2.1.3 Growing preference for personalized medicine in oncology
5.2.1.4 Advancements in genetic engineering
5.2.2 RESTRAINTS
5.2.2.1 Introduction of 3D printed models
5.2.2.2 Ethical concerns and regulatory restrictions
5.2.3 OPPORTUNITIES
5.2.3.1 Utilization of CRISPR in biomedical research
5.2.3.2 Rising demand for disease-specific models
5.2.4 CHALLENGES
5.2.4.1 Development of alternative animal testing methods
5.2.4.2 Genetic & Phenotypic variability
5.3 MARKET LANDSCAPE
5.3.1 HISTORY OF MICE MODELS
5.3.2 MICE MODEL GENERATION PROCESS
5.3.3 TECHNIQUES FOR MICE MODEL DEVELOPMENT
5.3.4 TECHNOLOGICAL ADVANCEMENTS
5.3.5 CONSIDERATIONS FOR MICE MODEL DEVELOPMENT
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 20 MARKET: SUPPLY CHAIN ANALYSIS
5.5 VALUE CHAIN ANALYSIS
FIGURE 21 MARKET: VALUE CHAIN ANALYSIS
5.6 PRICING ANALYSIS
TABLE 3 AVERAGE SELLING PRICE TREND OF MODEL TYPE, BY KEY PLAYER
5.6.1 AVERAGE SELLING PRICE TREND ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 22 MARKET: ECOSYSTEM ANALYSIS
5.7.1 MICE MODEL VENDORS
TABLE 4 MARKET: ROLE IN ECOSYSTEM, BY MICE MODEL VENDORS
5.7.2 MICE MODEL SERVICE VENDORS
TABLE 5 MARKET: ROLE IN ECOSYSTEM, BY SERVICE VENDOR
5.7.3 MICE MODEL END USERS
TABLE 6 MARKET: ROLE IN ECOSYSTEM, BY END USER
5.7.4 REGULATORY ORGANIZATIONS
TABLE 7 MARKET: ROLE IN ECOSYSTEM, BY REGULATORY ORGANIZATION
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9 PATENT ANALYSIS
5.9.1 METHODOLOGY
5.9.2 PATENTS FILED, BY DOCUMENT TYPE, 2014−2024
TABLE 8 PATENTS FILED (2014−2024)
5.9.3 INNOVATION & PATENT APPLICATIONS
FIGURE 24 TOTAL NUMBER OF PATENTS GRANTED (2014−2024)
5.9.4 TOP APPLICANTS
FIGURE 25 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS (2014−2024)
TABLE 9 TOP 20 PATENT OWNERS IN MARKET (2014−2024)
TABLE 10 PATENTS IN MARKET (2024)
5.10 KEY CONFERENCES & EVENTS
5.10.1 MARKET: KEY CONFERENCES & EVENTS (2024−2025)
TABLE 11 MARKET: CONFERENCES & EVENTS (2024−2025)
5.11 REGULATORY LANDSCAPE
5.11.1 REGULATORY ANALYSIS
5.11.1.1 North America
5.11.1.2 Europe
5.11.1.3 China
5.11.1.4 Japan
5.11.1.5 India
5.11.1.6 Australia
5.11.1.7 Brazil
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 MARKET: REGULATORY SCENARIO
5.12 PORTER’S FIVE FORCES ANALYSIS
TABLE 17 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 BARGAINING POWER OF SUPPLIERS
5.12.5 INTENSITY OF COMPETITIVE RIVALRY
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MARKET
TABLE 18 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR MICE MODELS & SERVICES
5.13.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS
5.13.3 BUYING CRITERIA FOR MARKET
FIGURE 27 KEY BUYING CRITERIA FOR END USERS
TABLE 19 BUYING CRITERIA FOR MICE MODEL TYPE & SERVICE, BY END USER
6 MICE MODEL MARKET, BY MODEL TYPE AND SERVICE (Page No. - 111)
6.1 INTRODUCTION
TABLE 20 MICE MODEL INDUSTRY, BY MODEL TYPE AND SERVICE, 2022–2029 (USD MILLION)
6.2 MODEL TYPES
TABLE 21 MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 22 NORTH AMERICA: MICE MODEL TYPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 23 EUROPE: MICE MODEL TYPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 24 ASIA PACIFIC: MICE MODEL TYPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 25 LATIN AMERICA: MICE MODEL TYPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 26 MIDDLE EAST: MICE MODEL TYPE MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 27 GCC COUNTRIES: MICE MODEL TYPE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 28 MARKET, BY TYPE, 2022–2029 (USD MILLION)
6.2.1 INBRED MICE
6.2.1.1 High utilization across research applications to propel market
TABLE 29 MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 30 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 31 EUROPE: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 33 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 34 MIDDLE EAST: MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 35 GCC COUNTRIES: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.2.2 GENETICALLY ENGINEERED MICE
6.2.2.1 Ability to induce mutations for CVD & cancer research to drive market
TABLE 36 MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 37 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 EUROPE: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 39 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 40 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 41 MIDDLE EAST: MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 42 GCC COUNTRIES: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.2.3 HYBRID/CONGENIC MICE
6.2.3.1 Growing focus on biomedical research to boost demand
TABLE 43 MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 44 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 45 EUROPE: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 46 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 47 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 MIDDLE EAST: MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 49 GCC COUNTRIES: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.2.4 OUTBRED MICE
6.2.4.1 Genetic diversity benefits to support market growth
TABLE 50 MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 51 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 52 EUROPE: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 53 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 MIDDLE EAST: MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 56 GCC COUNTRIES: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3 SERVICES
TABLE 57 MICE MODEL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 58 NORTH AMERICA: MICE MODEL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 59 EUROPE: MICE MODEL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 60 ASIA PACIFIC: MICE MODEL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 61 LATIN AMERICA: MICE MODEL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 62 MIDDLE EAST: MICE MODEL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 63 GCC COUNTRIES: MICE MODEL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 64 MICE MODEL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
6.3.1 BREEDING SERVICES
6.3.1.1 Customization of models for specific research applications to boost demand
TABLE 65 MICE MODEL BREEDING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 66 NORTH AMERICA: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67 EUROPE: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 68 ASIA PACIFIC: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 LATIN AMERICA: MICE MODEL BREEDING SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 MIDDLE EAST: MICE MODEL BREEDING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 71 GCC COUNTRIES: MICE MODEL BREEDING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
6.3.2 CRYOPRESERVATION SERVICES
6.3.2.1 Rising focus on preservation of novel mice models to propel market
TABLE 72 MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 73 NORTH AMERICA: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 EUROPE: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 75 ASIA PACIFIC: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 LATIN AMERICA: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 77 MIDDLE EAST: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY REGION 2022–2029 (USD MILLION)
TABLE 78 GCC COUNTRIES: MICE MODEL CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3.3 REDERIVATION SERVICES
6.3.3.1 Stringent quality assurance standards to fuel market
TABLE 79 MICE MODEL REDERIVATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 80 NORTH AMERICA: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 EUROPE: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 82 ASIA PACIFIC: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 LATIN AMERICA: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 84 MIDDLE EAST: MICE MODEL REDERIVATION SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 85 GCC COUNTRIES: MICE MODEL REDERIVATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3.4 QUARANTINE SERVICES
6.3.4.1 Rising demand for germ-free mice to support market growth
TABLE 86 MICE MODEL QUARANTINE SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 87 NORTH AMERICA: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88 EUROPE: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 ASIA PACIFIC: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 90 LATIN AMERICA: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 91 MIDDLE EAST: MICE MODEL QUARANTINE SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 92 GCC COUNTRIES: MICE MODEL QUARANTINE SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
6.3.5 OTHER SERVICES
TABLE 93 MICE MODEL OTHER SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 94 NORTH AMERICA: MICE MODEL OTHER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 95 EUROPE: MICE MODEL OTHER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 ASIA PACIFIC: MICE MODEL OTHER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 97 LATIN AMERICA: MICE MODEL OTHER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 98 MIDDLE EAST: MICE MODEL OTHER SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 99 GCC COUNTRIES: MICE MODEL OTHER SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7 MICE MODEL MARKET, BY TECHNOLOGY (Page No. - 147)
7.1 INTRODUCTION
TABLE 100 MICE MODEL INDUSTRY, BY TECHNOLOGY, 2022–2029 (USD MILLION)
7.2 CRISPR/CAS9
7.2.1 ADVANTAGES SUCH AS SIMPLIFIED DESIGN AND COST EFFICIENCY TO BOOST DEMAND
TABLE 101 CRISPR/CAS9 MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 102 NORTH AMERICA: CRISPR/CAS9 MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 EUROPE: CRISPR/CAS9 MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 ASIA PACIFIC: CRISPR/CAS9 MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 105 LATIN AMERICA: CRISPR/CAS9 MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106 MIDDLE EAST: CRISPR/CAS9 MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 107 GCC COUNTRIES: CRISPR/CAS9 MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.3 MICROINJECTION
7.3.1 LOW TOXICITY AND HIGH SUCCESS RATE TO PROPEL MARKET
TABLE 108 MICROINJECTION MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 109 NORTH AMERICA: MICROINJECTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 110 EUROPE: MICROINJECTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 111 ASIA PACIFIC: MICROINJECTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 LATIN AMERICA: MICROINJECTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 MIDDLE EAST: MICROINJECTION MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 114 GCC COUNTRIES: MICROINJECTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.4 EMBRYONIC STEM CELL INJECTION
7.4.1 RISING DEMAND FOR TARGETED MICE MODELS IN IMMUNOLOGICAL RESEARCH TO DRIVE MARKET
TABLE 115 EMBRYONIC STEM CELL INJECTION MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 116 NORTH AMERICA: EMBRYONIC STEM CELL INJECTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 117 EUROPE: EMBRYONIC STEM CELL INJECTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 ASIA PACIFIC: EMBRYONIC STEM CELL INJECTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119 LATIN AMERICA: EMBRYONIC STEM CELL INJECTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 120 MIDDLE EAST: EMBRYONIC STEM CELL INJECTION MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 121 GCC COUNTRIES: EMBRYONIC STEM CELL INJECTION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.5 NUCLEAR TRANSFER
7.5.1 POTENTIAL TO PRODUCE IDENTICAL MICE TO DRIVE MARKET
TABLE 122 NUCLEAR TRANSFER MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 123 NORTH AMERICA: NUCLEAR TRANSFER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 124 EUROPE: NUCLEAR TRANSFER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 ASIA PACIFIC: NUCLEAR TRANSFER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 LATIN AMERICA: NUCLEAR TRANSFER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 127 MIDDLE EAST: NUCLEAR TRANSFER MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 128 GCC COUNTRIES: NUCLEAR TRANSFER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
7.6 OTHER TECHNOLOGIES
TABLE 129 OTHER TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 130 NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 131 EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 134 MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 135 GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
8 MICE MODEL MARKET, BY THERAPEUTIC AREA (Page No. - 164)
8.1 INTRODUCTION
TABLE 136 MICE MODEL INDUSTRY, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
8.2 ONCOLOGY
8.2.1 GROWING FOCUS ON ONCOLOGY THERAPEUTIC DEVELOPMENT TO PROPEL MARKET
TABLE 137 MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 138 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 139 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 140 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 141 LATIN AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142 MIDDLE EAST: MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 143 GCC COUNTRIES: MARKET FOR ONCOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
8.3 METABOLIC DISEASES
8.3.1 RISING PREVALENCE OF DIABETES TO DRIVE MARKET
TABLE 144 MARKET FOR METABOLIC DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 145 NORTH AMERICA: MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 146 EUROPE: MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 147 ASIA PACIFIC: MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 148 LATIN AMERICA: MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 149 MIDDLE EAST: MARKET FOR METABOLIC DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 150 GCC COUNTRIES: MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
8.4 IMMUNOLOGY
8.4.1 INCREASING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO FUEL MARKET
TABLE 151 MARKET FOR IMMUNOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 152 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 153 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 154 ASIA PACIFIC: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 155 LATIN AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 156 MIDDLE EAST: MARKET FOR IMMUNOLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 157 GCC COUNTRIES: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
8.5 NEUROLOGY
8.5.1 INCREASING INVESTMENTS IN R&D FOR CNS DISEASES TO SUPPORT MARKET GROWTH
TABLE 158 MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 159 NORTH AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 160 EUROPE: MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 161 ASIA PACIFIC: MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 162 LATIN AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 163 MIDDLE EAST: MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD MILLION)
TABLE 164 GCC COUNTRIES: MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
8.6 CARDIOVASCULAR DISEASES
8.6.1 GROWING FOCUS ON TARGETED TREATMENTS FOR CVD TO BOOST DEMAND
TABLE 165 MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 166 NORTH AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 167 EUROPE: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 168 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 169 LATIN AMERICA: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 170 MIDDLE EAST: MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 171 GCC COUNTRIES: MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
8.7 OTHER THERAPEUTIC AREAS
TABLE 172 MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION)
TABLE 173 NORTH AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 174 EUROPE: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 175 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 176 LATIN AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 177 MIDDLE EAST: MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2022–2029 (USD MILLION)
TABLE 178 GCC COUNTRIES: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
9 MICE MODEL MARKET, BY APPLICATION (Page No. - 185)
9.1 INTRODUCTION
TABLE 179 MICE MODEL INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
9.2 DRUG DISCOVERY & DEVELOPMENT
9.2.1 RISING NUMBER OF CLINICAL TRIALS TO DRIVE MARKET
TABLE 180 MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2022–2029 (USD MILLION)
TABLE 181 NORTH AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 182 EUROPE: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 183 ASIA PACIFIC: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 184 LATIN AMERICA: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 185 MIDDLE EAST: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 186 GCC COUNTRIES: MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)
9.3 RESEARCH APPLICATIONS
9.3.1 RISING FUNDING FOR CANCER RESEARCH TO BOOST DEMAND
TABLE 187 MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 188 NORTH AMERICA: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 189 EUROPE: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 190 ASIA PACIFIC: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 191 LATIN AMERICA: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 192 MIDDLE EAST: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 193 GCC COUNTRIES: MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
9.4 PERSONALIZED MEDICINE
9.4.1 GROWING PREFERENCE FOR ONCOLOGY THERAPEUTICS TO PROPEL MARKET
TABLE 194 MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2022–2029 (USD MILLION)
TABLE 195 NORTH AMERICA: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 196 EUROPE: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 197 ASIA PACIFIC: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 198 LATIN AMERICA: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 199 MIDDLE EAST: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 200 GCC COUNTRIES: MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2022–2029 (USD MILLION)
10 MICE MODEL MARKET, BY END USER (Page No. - 196)
10.1 INTRODUCTION
TABLE 201 MICE MODEL INDUSTRY, BY END USER, 2022–2029 (USD MILLION)
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 RISING EXPENDITURE ON R&D FOR DRUG DEVELOPMENT TO BOOST DEMAND
TABLE 202 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 203 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 204 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 205 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 206 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 207 MIDDLE EAST: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 208 GCC COUNTRIES: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
10.3 ACADEMIC & RESEARCH INSTITUTES
10.3.1 INCREASING FUNDING INITIATIVES FOR LIFE SCIENCES R&D TO SUPPORT MARKET GROWTH
TABLE 209 MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 210 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 211 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 212 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 213 LATIN AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 214 MIDDLE EAST: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 215 GCC COUNTRIES: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
10.4 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS
10.4.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES TO PROPEL MARKET
TABLE 216 MARKET FOR CROS & CDMOS, BY REGION, 2022–2029 (USD MILLION)
TABLE 217 NORTH AMERICA: MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 218 EUROPE: MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 219 ASIA PACIFIC: MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 220 LATIN AMERICA: MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 USD MILLION)
TABLE 221 MIDDLE EAST: MARKET FOR CROS & CDMOS, BY REGION, 2022–2029 (USD MILLION)
TABLE 222 GCC COUNTRIES: MARKET FOR CROS & CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
11 MICE MODEL MARKET, BY REGION (Page No. - 207)
11.1 INTRODUCTION
TABLE 223 MICE MODEL INDUSTRY, BY REGION, 2022–2029 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 28 NORTH AMERICA: MICE MODEL MARKET SNAPSHOT
TABLE 224 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 225 NORTH AMERICA: MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 226 NORTH AMERICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 227 NORTH AMERICA: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 228 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 229 NORTH AMERICA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 230 NORTH AMERICA: MICE MODEL INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 231 NORTH AMERICA: MARKET, BY END USER, 2022–2029 (USD MILLION
11.2.2 US
11.2.2.1 Rising production of monoclonal antibodies to fuel market for mice models
TABLE 232 US: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 233 US: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 US: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 235 US: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 236 US: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 237 US: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 238 US: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
11.2.3 CANADA
11.2.3.1 Growth in stem cell research activities to support market growth
TABLE 239 CANADA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 240 CANADA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 241 CANADA: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 242 CANADA: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 243 CANADA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 244 CANADA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 245 CANADA: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
TABLE 246 EUROPE: MICE MODEL MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 247 EUROPE: MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 248 EUROPE: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 249 EUROPE: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 250 EUROPE: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 251 EUROPE: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 252 EUROPE: MICE MODEL INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 253 EUROPE: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 Growing biotechnology industry to drive market
TABLE 254 GERMANY: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 255 GERMANY: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 256 GERMANY: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 257 GERMANY: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 258 GERMANY: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 259 GERMANY: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 260 GERMANY: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.3 UK
11.3.3.1 Increasing focus on cancer research to propel market
TABLE 261 UK: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 262 UK: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 UK: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 264 UK: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 265 UK: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 266 UK: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 267 UK: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Increased investments in proteomics and genomics to fuel growth
TABLE 268 FRANCE: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 269 FRANCE: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 270 FRANCE: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 271 FRANCE: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 272 FRANCE: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 273 FRANCE: MICE MODEL INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 274 FRANCE: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Growth in pharmaceutical and biotechnology industry to drive market
TABLE 275 ITALY: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 276 ITALY: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 277 ITALY: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 278 ITALY: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 279 ITALY: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 280 ITALY: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 281 ITALY: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Extensive R&D pipeline to support market growth
TABLE 282 SPAIN: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 283 SPAIN: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 284 SPAIN: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 285 SPAIN: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 286 SPAIN: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 287 SPAIN: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 288 SPAIN: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 289 REST OF EUROPE: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 290 REST OF EUROPE: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 291 REST OF EUROPE: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 292 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 293 REST OF EUROPE: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 294 REST OF EUROPE: MICE MODEL INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 295 REST OF EUROPE: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4 ASIA PACIFIC
11.4.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 29 ASIA PACIFIC: MICE MODEL MARKET SNAPSHOT
TABLE 296 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 297 ASIA PACIFIC: MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 298 ASIA PACIFIC: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 299 ASIA PACIFIC: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 300 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 301 ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 302 ASIA PACIFIC: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 303 ASIA PACIFIC: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Growing funding and investments in life sciences research to drive market
TABLE 304 CHINA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 305 CHINA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 306 CHINA: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 307 CHINA: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 308 CHINA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 309 CHINA: MICE MODEL INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 310 CHINA: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.3 JAPAN
11.4.3.1 Increasing focus on personalized diagnostics products to drive market
TABLE 311 JAPAN: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 312 JAPAN: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 313 JAPAN: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 314 JAPAN: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 315 JAPAN: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 316 JAPAN: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 317 JAPAN: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.4 INDIA
11.4.4.1 Increasing initiatives for drug discovery to boost market growth
TABLE 318 INDIA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 319 INDIA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 320 INDIA: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 321 INDIA: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 322 INDIA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 323 INDIA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 324 INDIA: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.5 AUSTRALIA
11.4.5.1 High number of research institutes to favor market growth
TABLE 325 AUSTRALIA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 326 AUSTRALIA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 327 AUSTRALIA: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 328 AUSTRALIA: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 329 AUSTRALIA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 330 AUSTRALIA: MICE MODEL INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 331 AUSTRALIA: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.6 SOUTH KOREA
11.4.6.1 Rising R&D investments in drug development to fuel uptake of genetically engineered mice models
TABLE 332 SOUTH KOREA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 333 SOUTH KOREA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 334 SOUTH KOREA: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 335 SOUTH KOREA: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 336 SOUTH KOREA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 337 SOUTH KOREA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 338 SOUTH KOREA: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.4.7 REST OF ASIA PACIFIC
TABLE 339 REST OF ASIA PACIFIC: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 340 REST OF ASIA PACIFIC: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 341 REST OF ASIA PACIFIC: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 342 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 343 REST OF ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 344 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 345 REST OF ASIA PACIFIC: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 346 LATIN AMERICA: MICE MODEL MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 347 LATIN AMERICA: MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 348 LATIN AMERICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 349 LATIN AMERICA: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 350 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 351 LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 352 LATIN AMERICA: MICE MODEL INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 353 LATIN AMERICA: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
11.5.2 BRAZIL
11.5.2.1 Increasing Investments in Biopharmaceutical research to propel market growth
TABLE 354 BRAZIL: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 355 BRAZIL: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 356 BRAZIL: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 357 BRAZIL: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 358 BRAZIL: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 359 BRAZIL: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 360 BRAZIL: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
11.5.3 MEXICO
11.5.3.1 Expanding healthcare ecosystem to support market growth
TABLE 361 MEXICO: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 362 MEXICO: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 363 MEXICO: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 364 MEXICO: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 365 MEXICO: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 366 MEXICO: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 367 MEXICO: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
11.5.4 REST OF LATIN AMERICA
TABLE 368 REST OF LATIN AMERICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 369 REST OF LATIN AMERICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 370 REST OF LATIN AMERICA: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 371 REST OF LATIN AMERICA: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 372 REST OF LATIN AMERICA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 373 REST OF LATIN AMERICA: MICE MODEL INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 374 REST OF LATIN AMERICA: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
11.6 MIDDLE EAST
11.6.1 MIDDLE EAST: RECESSION IMPACT
TABLE 375 MIDDLE EAST: MICE MODEL MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 376 MIDDLE EAST: MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 377 MIDDLE EAST: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 378 MIDDLE EAST: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 379 MIDDLE EAST: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 380 MIDDLE EAST: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 381 MIDDLE EAST: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 382 MIDDLE EAST: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
11.6.2 GCC COUNTRIES
TABLE 383 GCC COUNTRIES: MICE MODEL MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 384 GCC COUNTRIES: MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 385 GCC COUNTRIES: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 386 GCC COUNTRIES: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 387 GCC COUNTRIES: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 388 GCC COUNTRIES: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 389 GCC COUNTRIES: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 390 GCC COUNTRIES: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
11.6.2.1 SAUDI ARABIA
11.6.2.1.1 Growing focus on advancement of healthcare sector to boost market growth
TABLE 391 SAUDI ARABIA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 392 SAUDI ARABIA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 393 SAUDI ARABIA: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 394 SAUDI ARABIA: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 395 SAUDI ARABIA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 396 SAUDI ARABIA: MICE MODEL INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 397 SAUDI ARABIA: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION)
11.6.2.2 UNITED ARAB EMIRATES
11.6.2.2.1 Increasing R&D activities and growing demand for personalized medicine to propel market
TABLE 398 UNITED ARAB EMIRATES: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 399 UNITED ARAB EMIRATES: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 400 UNITED ARAB EMIRATES: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 401 UNITED ARAB EMIRATES: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 402 UNITED ARAB EMIRATES: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 403 UNITED ARAB EMIRATES: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 404 UNITED ARAB EMIRATES: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
11.6.2.3 REST OF GCC COUNTRIES
TABLE 405 REST OF GCC COUNTRIES: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 406 REST OF GCC COUNTRIES: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 407 REST OF GCC COUNTRIES: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 408 REST OF GCC COUNTRIES: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 409 REST OF GCC COUNTRIES: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 410 REST OF GCC COUNTRIES: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 411 REST OF GCC COUNTRIES: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
11.6.3 REST OF MIDDLE EAST
TABLE 412 REST OF MIDDLE EAST: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 413 REST OF MIDDLE EAST: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 414 REST OF MIDDLE EAST: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 415 REST OF MIDDLE EAST: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 416 REST OF MIDDLE EAST: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 417 REST OF MIDDLE EAST: MICE MODEL INDUSTRY, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 418 REST OF MIDDLE EAST: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
11.7 AFRICA
11.7.1 GROWING PRECISION MEDICINE INITIATIVES TO FUEL MARKET GROWTH
11.7.2 AFRICA: RECESSION IMPACT
TABLE 419 AFRICA: MICE MODEL MARKET, BY MODEL TYPE & SERVICE, 2022–2029 (USD MILLION)
TABLE 420 AFRICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 421 AFRICA: MARKET, BY SERVICE, 2022–2029 (USD MILLION)
TABLE 422 AFRICA: MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
TABLE 423 AFRICA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
TABLE 424 AFRICA: MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 425 AFRICA: MICE MODEL MARKET, BY END USER, 2022–2029 (USD MILLION
12 COMPETITIVE LANDSCAPE (Page No. - 294)
12.1 OVERVIEW
12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
TABLE 426 KEY PLAYERS STRATEGIES IN MICE MODEL MARKET, 2021−2024
12.3 REVENUE SHARE ANALYSIS
FIGURE 30 REVENUE SHARE ANALYSIS FOR KEY COMPANIES, 2019–2023 (USD MILLION)
12.4 MARKET SHARE ANALYSIS
FIGURE 31 MICE MODEL INDUSTRY SHARE ANALYSIS OF KEY PLAYERS (2023)
TABLE 427 MICE MODEL INDUSTRY: INTENSITY OF COMPETITIVE RIVALRY
12.5 FINANCIAL METRICS
12.6 BRAND/PRODUCT COMPARATIVE ANALYSIS
12.6.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL
FIGURE 32 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL
12.6.1.1 CHARLES RIVER LABORATORIES
12.6.1.2 THE JACKSON LABORATORY
12.6.1.3 INOTIV
12.6.1.4 TACONIC BIOSCIENCES, INC.
12.6.1.5 BIOCYTOGEN
12.6.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY SERVICE
FIGURE 33 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY SERVICE
12.6.2.1 CHARLES RIVER LABORATORIES
12.6.2.2 THE JACKSON LABORATORY
12.6.2.3 INOTIV
12.6.2.4 TACONIC BIOSCIENCES, INC.
12.6.2.5 BIOCYTOGEN
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS (2023)
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
FIGURE 34 MICE MODEL INDUSTRY: COMPANY EVALUATION MATRIX (KEY PLAYERS) 2023,
12.7.5 COMPANY FOOTPRINT (KEY PLAYERS)
FIGURE 35 MICE MODEL INDUSTRY: COMPANY FOOTPRINT KEY PLAYERS
TABLE 428 INDUSTRY FOOTPRINT (KEY PLAYERS)
12.7.6 PRODUCT & SERVICE FOOTPRINT
TABLE 429 MICE MODEL INDUSTRY: PRODUCT & SERVICE FOOTPRINT (KEY PLAYERS)
12.7.7 REGIONAL FOOTPRINT (KEY PLAYERS)
TABLE 430 REGIONAL FOOTPRINT (KEY PLAYERS)
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
FIGURE 36 MICE MODEL INDUSTRY: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
12.8.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 431 MICE MODEL INDUSTRY: KEY STARTUPS/SMES
TABLE 432 MICE MODEL INDUSTRY: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES
TABLE 433 MICE MODEL INDUSTRY: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2024
12.9.2 DEALS
TABLE 434 MICE MODEL INDUSTRY: DEALS, JANUARY 2021−JANUARY 2024
12.9.3 EXPANSIONS
TABLE 435 MICE MODEL INDUSTRY: EXPANSIONS, JANUARY 2021−JANUARY 2024
13 COMPANY PROFILES (Page No. - 313)
13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 CHARLES RIVER LABORATORIES
TABLE 436 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 37 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
TABLE 437 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED
TABLE 438 CHARLES RIVER LABORATORIES: DEALS
TABLE 439 CHARLES RIVER LABORATORIES: EXPANSIONS
13.1.2 INOTIV
TABLE 440 INOTIV: BUSINESS OVERVIEW
TABLE 441 INOTIV: PRODUCTS/SERVICES OFFERED
TABLE 442 INOTIV: PRODUCT LAUNCHES
TABLE 443 INOTIV: DEALS
TABLE 444 INOTIV: EXPANSIONS
13.1.3 THE JACKSON LABORATORY
TABLE 445 THE JACKSON LABORATORY: BUSINESS OVERVIEW
TABLE 446 THE JACKSON LABORATORY: PRODUCTS/SERVICES OFFERED
TABLE 447 THE JACKSON LABORATORY: PRODUCT LAUNCHES
TABLE 448 THE JACKSON LABORATORY: DEALS
13.1.4 SHANGHAI MODEL ORGANISMS CENTER, INC.
TABLE 449 SHANGHAI MODEL ORGANISMS CENTER, INC.: BUSINESS OVERVIEW
FIGURE 40 SHANGHAI MODEL ORGANISMS CENTER, INC.: COMPANY SNAPSHOT (2022)
TABLE 450 SHANGHAI MODEL ORGANISMS CENTER, INC.: PRODUCTS/SERVICES OFFERED
13.1.5 JSR CORPORATION
TABLE 451 JSR CORPORATION: BUSINESS OVERVIEW
FIGURE 41 JSR CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 452 JSR CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 453 JSR CORPORATION: DEALS
13.1.6 BIOCYTOGEN
TABLE 454 BIOCYTOGEN: BUSINESS OVERVIEW
FIGURE 42 BIOCYTOGEN: COMPANY SNAPSHOT (2022)
TABLE 455 BIOCYTOGEN: PRODUCTS/SERVICES OFFERED
TABLE 456 BIOCYTOGEN: PRODUCT LAUNCHES
TABLE 457 BIOCYTOGEN: DEALS
TABLE 458 BIOCYTOGEN: EXPANSIONS
13.1.7 TRANS GENIC INC.
TABLE 459 TRANS GENIC INC.: BUSINESS OVERVIEW
FIGURE 43 TRANS GENIC INC.: COMPANY SNAPSHOT (2023)
TABLE 460 TRANS GENIC, INC.: PRODUCTS/SERVICES OFFERED
13.1.8 HARBOUR BIOMED
TABLE 461 HARBOUR BIOMED: BUSINESS OVERVIEW
FIGURE 44 HARBOUR BIOMED: COMPANY SNAPSHOT (2022)
TABLE 462 HARBOUR BIOMED: PRODUCTS/SERVICES OFFERED
TABLE 463 HARBOUR BIOMED: OTHER DEVELOPMENTS
13.1.9 GENOWAY
TABLE 464 GENOWAY: BUSINESS OVERVIEW
FIGURE 45 GENOWAY: COMPANY SNAPSHOT (2022)
TABLE 465 GENOWAY: PRODUCTS/SERVICES OFFERED
TABLE 466 GENOWAY: DEALS
13.1.10 GEMPHARMATECH
TABLE 467 GEMPHARMATECH: BUSINESS OVERVIEW
TABLE 468 GEMPHARMATECH: PRODUCTS/SERVICES OFFERED
TABLE 469 GEMPHARMATECH: DEALS
TABLE 470 GEMPHARMATECH: EXPANSIONS
13.1.11 CYAGEN
TABLE 471 CYAGEN: BUSINESS OVERVIEW
TABLE 472 CYAGEN: PRODUCTS/SERVICES OFFERED
13.1.12 OZGENE PTY LTD.
TABLE 473 OZGENE PTY LTD.: BUSINESS OVERVIEW
TABLE 474 OZGENE PTY LTD.: PRODUCTS/SERVICES OFFERED
TABLE 475 DEALS
13.1.13 TACONIC BIOSCIENCES, INC.
TABLE 476 TACONIC BIOSCIENCES, INC.: BUSINESS OVERVIEW
TABLE 477 TACONIC BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 478 TACONIC BIOSCIENCES, INC.: PRODUCT LAUNCHES
TABLE 479 TACONIC BIOSCIENCES, INC.: DEALS
13.1.14 TRANSCURE BIOSERVICES
TABLE 480 TRANSCURE BIOSERVICES: BUSINESS OVERVIEW
TABLE 481 TRANSCURE BIOSERVICES: PRODUCTS/SERVICES OFFERED
13.1.15 MARSHALL BIORESOURCES
TABLE 482 MARSHALL BIORESOURCES: BUSINESS OVERVIEW
TABLE 483 MARSHALL BIORESOURCES: PRODUCTS/SERVICES OFFERED
13.1.16 VIVO BIO TECH LTD.
TABLE 484 VIVO BIO TECH LTD.: BUSINESS OVERVIEW
FIGURE 46 VIVO BIO TECH LTD: COMPANY SNAPSHOT (2022)
TABLE 485 VIVO BIO TECH LTD.: PRODUCTS/SERVICES OFFERED
13.1.17 INGENIOUS TARGETING LABORATORY
TABLE 486 INGENIOUS TARGETING LABORATORY: BUSINESS OVERVIEW
TABLE 487 INGENIOUS TARGETING LABORATORY: PRODUCTS/SERVICES OFFERED
13.1.18 JANVIER LABS
TABLE 488 JANVIER LABS: BUSINESS OVERVIEW
TABLE 489 JANVIER LABS: PRODUCTS/SERVICES OFFERED
13.2 OTHER PLAYERS
13.2.1 APPLIED STEMCELL
TABLE 490 APPLIED STEMCELL: BUSINESS OVERVIEW
13.2.2 CREATIVE ANIMODEL
TABLE 491 CREATIVE ANIMODEL: BUSINESS OVERVIEW
13.2.3 JOINN LABORATORIES (CHINA) CO., LTD.
TABLE 492 JOINN LABORATORIES (CHINA) CO., LTD.: BUSINESS OVERVIEW
13.2.4 CREATIVE BIOLABS
TABLE 493 CREATIVE BIOLABS: BUSINESS OVERVIEW
13.2.5 CRESCENDO BIOLOGICS
TABLE 494 CRESCENDO BIOLOGICS: BUSINESS OVERVIEW
13.2.6 ARAGEN LIFE SCIENCES
TABLE 495 ARAGEN LIFE SCIENCES: BUSINESS OVERVIEW
13.2.7 POLYGENE
TABLE 496 POLYGENE: BUSINESS OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX (Page No. - 379)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global mice model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research:
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the mice model market. The secondary sources used for this study include International Mouse Phenotyping Consortium (IMPC), Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), European Molecular Biology Laboratory−European Bioinformatics Institute (EMBL-EBI), Swiss Laboratory Animal Science Association (SGV), Medical Research Council (MRC), Asian Mouse Mutagenesis Resource Association (AMMRA), Department of Biotechnology (DBT) (India), World Health Organization (WHO), United States Food and Drug Administration (US FDA), Annual Reports, SEC Filings, Investor Presentations, Research Journals, Press Releases, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research:
Extensive primary research was conducted after acquiring basic knowledge about the global mice model market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical and biotechnology companies, CROs, and academic & research institutes) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, across six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and the Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This preliminary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation:
Both top-down and bottom-up approaches were used to estimate and validate the total size of the mice model market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Bottom-up Approach:
- The key players in the industry and market have been identified through extensive secondary research.
- The revenues generated from the mice model market business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
To know about the assumptions considered for the study, Request for Free Sample Report
Top-down Approach:
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation:
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition:
An animal model is a valuable resource in biomedical research, chosen for its ability to replicate certain aspects of biological processes or diseases observed in humans. A mouse model is a genetically engineered or naturally occurring mouse strain used in biomedical research to mimic human diseases or conditions. These models are valuable for their biological similarity to humans, ability to be genetically manipulated, and cost-effectiveness, enabling researchers to study disease mechanisms and test novel drug therapies efficiently. Mice share over 95% of the human DNA and are biologically similar to humans, thereby being susceptible to similar diseases due to genetic build-up.
The scope of the report encompasses mice models and associated services offered by companies like Charles River Laboratories and THE JACKSON LABORATORY.
Stakeholders:
- Manufacturers and distributors of mice model products
- Mice model service providers
- Pharmaceutical and biotechnology companies
- Market research and consulting firms
- R&D centers
- Researchers and scientists
- Regulatory authorities & institutions
- Academic & research institutes
- CROs & CDMOs
Report Objectives:
- To define, describe, and forecast the global mice model market based on model type & service, technology, therapeutic area, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global mice model market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the mice model market
- To benchmark players in the mice model market using the “Company Evaluation Matrix” framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis:
- Further breakdown of the Rest of Europe mice model market, by country
- Further breakdown of the Rest of Asia Pacific mice model market, by country
- Further breakdown of the Rest of Latin America mice model market, by country
- Further breakdown of the Rest of Middle East mice model market, by country
- Further breakdown of the Rest of GCC Countries mice model market, by country
Company Information:
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis:
- Further breakdown of the other technologies and other therapeutic area into subsegments
- Cross-segment analysis
Generating Response ...
Growth opportunities and latent adjacency in Mice Model Market